Abstract 1589P
Background
In addition to the structural/medical barriers that trial centres face in including patients, the disparities that patients face prevents some groups from receiving the expected benefit from the studies and the results from representing the entire population. This study assessed the barriers to recruiting individuals in phase one trials who were referred to clinical research facility located in central London.
Methods
Records of patients who were referred to Guy's Cancer Early Phase Trials Unit between January and December 2023 were retrospectively reviewed. Baseline patient characteristics and barriers to trial enrolment were recorded and descriptive statistics were presented. The distrubition of new referrals by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was also assessed by comparing with our group's historic data published in 2013 in Journal of Clinical Oncology.
Results
We reviewed 206 new patients in 2023. Median age of the group was 63, and 52.4% of patient were male. GI, thoracic, gyneacological and urological malignancies were the most common tumour groups (37%, 19%, 18%, and 14% respectively). Of whole group, 33.9% of patients were referred after two lines of previous treatment. 37 patients (17.9%) were recruited to a trial annually. Most common barrier to be recruited to a trial is that the center has no potential trial to offer (N=59, 35.9%), followed by failure to meet radiological criteria (11.2%), and poor performance status (10.0%) 22 patients (10.6%) were from most deprivated (IMD 1-2) background. Our historic data from 2013 showed 21.9% of patients had been referred from most deprivated background. There was a white-ethnicitiy domination in current and historic data (71.5% and 74.2%, retrospectively).
Conclusions
An increasing number of new patients are being referred to our centre. Among the prominent recruitment barriers are the lack of appropriate studies and non-compliance with medical criteria. The decrease in the rate of patients from low socioeconomic backgrounds is striking compared to the historical data of our center. Further efforts should be made to identify the potential causes of this situation and to improve it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10